Paronychia induced by the epidermal growth factor receptor inhibitor cetuximab. (September 2013)

• Record Type: Journal Article
• Authors: Lee, Soo Lin; Tan, Boon Seang; Chan, Lee Chin
• Is Part Of: Journal of oncology pharmacy practice. Volume 19:Number 3(2013)
• Page Start: 273
• Page End: 278
• Publication Date: 2013-09
• Subjects: Cetuximab -- epidermal growth factor inhibitor -- monoclonal antibody -- metastatic colorectal cancer -- paronychia -- periungual granulation -- cutaneous reactions; Cancer -- Chemotherapy -- Periodicals; Clinical pharmacology -- Periodicals; 616.994061
• DOI: 10.1177/1078155212461289
• Languages: English
• ISSNs: 1078-1552

Abstract

While the development of epidermal growth factor receptor inhibitors has been hailed as a remarkable triumph in the field of oncology, it has inherited with it a host of cutaneous side-effects that have been increasingly observed in a substantial number of patients in the recent years. One cutaneous manifestation that may inflict significant pain and affect activities of daily living among some of the patients receiving epidermal growth factor receptor inhibitors is paronychia. A case of paronychia associated with the use of cetuximab in the management of KRAS wild-type midrectal adenocarcinoma along with its management has been described.